(Press-News.org) Contact information: Amy Mone
amone1@jhmi.edu
410-614-2915
Johns Hopkins Medicine
Small molecule shows promise as anti-cancer therapy
Johns Hopkins scientists say a previously known but little studied chemical compound targets and shuts down a common cancer process. In studies of laboratory-grown human tumor cell lines, the drug disrupted tumor cell division and prevented growth of advanced cancer cells.
In a study described in the January 13 issue of Cancer-Cell, Marikki Laiho, M.D., Ph.D., and her colleagues say their work focused on the ability of a chemical dubbed BMH-21 to sabotage the transcription pathway RNA Polymerase pathway (POL I), shutting down the ability of mutant cancer genes to communicate with cells and replicate.
Laiho's research linked the pathway to p53 gene activity. P53 is a tumor suppressor gene, a protein that regulates cell growth, and it is the most frequently mutated suppressor gene in cancer.
Transcription pathways are the means by which certain proteins that direct cell division are put into action by cells. Uncontrolled cell division is a hallmark of cancer, and BMH-21 has demonstrated an ability to bind to the DNA of cancer cells and completely shut down this transcription pathway.
"Without this transcription machinery, cancer cells cannot function," says Marikki Laiho, M.D., Ph.D., professor of Radiation Oncology and Molecular Radiation Sciences at Johns Hopkins and senior author on the study.
Laiho said BMH-21 was identified using by screening a library of chemical compounds known to have potential for anticancer activity based on their chemical structure and capabilities. Specifically, they looked for the ability of those compounds to interfere with transcription in human tumor cells obtained through the National Cancer Institute's collection of 60 human tumor cell lines of nine different cancer types, including melanoma and colon cancer.
BMH-21 first jumped out, Laiho said, demonstrating potent action against melanoma and colon cancer cells. In fact, in these studies, the drug functioned better in upsetting these cancer cells' activities than many FDA-approved cancer drugs.
BMH-21 also appears to overcome the tendency of cancer cells to resist chemotherapeutic agents because it finds and targets proteins and shuts down the communication pathways that cells use to continue dividing.
"One of the challenges of current cancer therapies, including new targeted therapies, is a cancer cell's ability to overcome a treatment's anticancer properties. The characteristics of a cancer cell and its circuitry is very complex and results in many changes and mutations that allow the cells to continue to thrive despite cancer treatments," said Laiho.
While the findings with BMH-21 are promising, Laiho cautions much more study of the compound is needed before it would be ready for studies in patients. She and her team are continuing studies of the drug in animal models to further reveal the drug's potential against cancer and possible toxicities, and to determine dosage.
The transcription machinery the compound shuts down is common among all cancer cell types, so the researchers believe it has therapeutic potential across many tumor types.
Laiho is currently collaborating with Kimmel Cancer Center drug development experts as well as multiple myeloma blood cancer, medullary thyroid cancer, and prostate cancer experts to further explore the drug's cancer-fighting abilities. She also is collaborating with investigators at a laboratory in Helsinki, Finland, where she maintains an affiliation.
###
In addition to Laiho, other members of the research team include Karita Peltonen, Laureen Colis, Hester Liu, Rishi Trivedi, Michael S. Moubarek, Henna M. Moore, Bayoan Bai, Michelle Rudek, and Charles J. Bieberich.
The research was supported by the Academy of Finland, Biomedicum Helsinki Foundation, Cancer Society Finland, Finnish Cultural Foundation, Patrick C. Walsh Cancer Research Fund, the National Institutes of Health, Johns Hopkins University start-up funds, and the Analytical Pharmacology Core of the Johns Hopkins Kimmel Cancer Center.
On the Web:
http://www.hopkinscancer.org
http://www.hopkinsmedicine.org/radiation_oncology/
Small molecule shows promise as anti-cancer therapy
2014-01-14
ELSE PRESS RELEASES FROM THIS DATE:
NASA adds up Tropical Cyclone Colin's rainfall rates
2014-01-14
NASA adds up Tropical Cyclone Colin's rainfall rates
Tropical Cyclone Colin continued moving through the Southern Indian Ocean on January 13 while NASA's TRMM satellite passed overhead and calculated the rates in which rain was falling throughout the storm.
The ...
Viral microRNAs responsible for causing AIDS-related cancer, new USC study shows
2014-01-14
Viral microRNAs responsible for causing AIDS-related cancer, new USC study shows
Molecular cluster and its cellular targets could help with drug development
LOS ANGELES - For the first time, scientists and engineers have identified ...
Passing bowls family-style teaches day-care kids to respond to hunger cues, fights obesity
2014-01-14
Passing bowls family-style teaches day-care kids to respond to hunger cues, fights obesity
URBANA, Ill. – When children and child-care providers sit around a table together at mealtime, passing ...
Tricky protein may help HIV vaccine development
2014-01-14
Tricky protein may help HIV vaccine development
Newly described 3-part protein will help guide future efforts at Duke
DURHAM, N.C. -- Duke scientists have taken aim at what may be an Achilles' heel of the HIV virus.
Combining expertise in biochemistry, immunology and advanced ...
Primates: Now with only half the calories!
2014-01-14
Primates: Now with only half the calories!
Lincoln Park Zoo and an international team of scientists uncover new information about primates that could lead to new understanding about human health and longevity
(Chicago – Jan. 13, 2014) -- New research shows that humans and ...
Keeping stem cells pluripotent
2014-01-14
Keeping stem cells pluripotent
By blocking key signal, researchers maintain embryonic stem cells in vital, undifferentiated state
While the ability of human embryonic stem cells (hESCs) to become any type of mature cell, from neuron to heart to skin and bone, ...
Scientists develop promising drug candidates for pain, addiction
2014-01-14
Scientists develop promising drug candidates for pain, addiction
JUPITER, FL, January 13, 2014 – Scientists from the Florida campus of The Scripps Research Institute (TSRI) have described a pair of drug candidates that advance the search for new treatments for ...
New report looks at how states' restrictions on ACA implementation are affecting access
2014-01-14
New report looks at how states' restrictions on ACA implementation are affecting access
In restrictive states, community health centers report hampered ability to help the uninsured, limiting potential coverage
WASHINGTON ...
Gene variation associated with brain atrophy in mild cognitive impairment
2014-01-14
Gene variation associated with brain atrophy in mild cognitive impairment
OAK BROOK, Ill. – The presence of a gene variant in people with mild cognitive impairment (MCI) is associated with accelerated rates of brain atrophy, according to a new study ...
Little but lethal -- small RNAs coordinate bacterial attack on epithelial cells
2014-01-14
Little but lethal -- small RNAs coordinate bacterial attack on epithelial cells
Two small RNAs (sRNAs) working in concert enable the deadly enterohemorrhagic Escherichia coli (EHEC) 0157:H7 to attach to and initiate infection in epithelial cells that line the ...